NEWRON PHARMACEUT. EO-,20/ IT0004147952 /
| 2024-11-15 11:00:52 PM | Chg. -0.280 | Volume | Bid11:00:52 PM | Ask11:00:52 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 7.760EUR | -3.48% | - Turnover: - |
7.760Bid Size: - | 7.900Ask Size: - | 138.75 mill.EUR | - | - |
Assets
| 2017 IFRS in mill. EUR |
2018 IFRS in mill. EUR |
2019 IFRS in mill. EUR |
2020 IFRS in mill. EUR |
2021 IFRS in mill. EUR |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | .1000 | .1000 | .1000 | .1000 | .0900 | ||||||
| Intangible Assets | 0.0000 | 0.0000 | .0200 | .0100 | .0100 | ||||||
| Long-Term Investments | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | ||||||
| Fixed Assets | .2000 | .2000 | .3000 | 13.3000 | 11.1000 | ||||||
| Inventories | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | ||||||
| Accounts Receivable | - | - | - | - | - | ||||||
| Cash and Cash Equivalents | 56.3000 | 27.6000 | 22.1000 | 13.2000 | 25 | ||||||
| Current Assets | 72.8000 | 59.5000 | 59.9000 | 37.9000 | 39.4000 | ||||||
| Total Assets | 73 | 59.7000 | 60.3000 | 51.2000 | 50.5000 | ||||||
Liabilities
| 2017 IFRS in mill. EUR |
2018 IFRS in mill. EUR |
2019 IFRS in mill. EUR |
2020 IFRS in mill. EUR |
2021 IFRS in mill. EUR |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 4.7000 | 4.3000 | 5.5000 | 6.7000 | 3.5000 | ||||||
| Long-term debt | - | - | 16.7000 | 25.7000 | 42.5000 | ||||||
| Liabilities to Banks | 0.0000 | 0.0000 | 16.7000 | 25.7000 | 42.5000 | ||||||
| Provisions | - | - | - | - | - | ||||||
| Liabilities | 5.3000 | 4.9000 | 23.5000 | 34 | 47.4000 | ||||||
| Share Capital | 3.6000 | 3.6000 | 3.6000 | 3.6000 | 3.6000 | ||||||
| Total Equity | 67.7000 | 54.8000 | 36.8000 | 17.2000 | 3.1000 | ||||||
| Minority Interests | - | - | - | - | - | ||||||
| Total liabilities equity | 73 | 59.7000 | 60.3000 | 51.2000 | 50.5000 | ||||||
Income Statement
| 2017 IFRS in mill. EUR |
2018 IFRS in mill. EUR |
2019 IFRS in mill. EUR |
2020 IFRS in mill. EUR |
2021 IFRS in mill. EUR |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 13.4000 | 4 | 7 | 5.3000 | 5.8000 | ||||||
| Depreciation (total) | - | - | - | - | - | ||||||
| Operating Result | -4.3000 | -15 | -20.9000 | -18.1000 | -12.4000 | ||||||
| Interest Income | - | - | - | - | - | ||||||
| Income Before Taxes | -5.3000 | -15 | -20.2000 | -19.6000 | -14.9000 | ||||||
| Income Taxes | 0.0000 | 0.0000 | 0.0000 | -1.4000 | 0.0000 | ||||||
| Minority Interests Profit | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | ||||||
| Net Income | -5.3000 | -15 | -20.2000 | -21 | -14.9000 | ||||||
Per Share
Cash Flow
| 2017 IFRS in mill. EUR |
2018 IFRS in mill. EUR |
2019 IFRS in mill. EUR |
2020 IFRS in mill. EUR |
2021 IFRS in mill. EUR |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | -8.4000 | -16.1000 | -22.2000 | -15.6000 | -11.4000 | ||||||
| Cash Flow from Investing Activities | -.2000 | 3 | -.9000 | -.6000 | 8.4000 | ||||||
| Cash Flow from Financing | 22 | .1000 | 17.6000 | 7.4000 | 14.8000 | ||||||
| Decrease / Increase in Cash | 13.3000 | -13 | -5.6000 | -8.8000 | 11.8000 | ||||||
| Employees | 23 | 24 | 26 | 23 | 25 | ||||||
